newsfilter
← Latest News
Business Wire·

Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

Durable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment. Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel